What are the clinical features of Anti-DM5 (Dermyositis-specific autoantibody 5)-associated idiopathic inflammatory myopathy, including skin and systemic manifestations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Anti-DM5 (Dermyositis-specific autoantibody 5)-associated idiopathic inflammatory myopathy is characterized by aggressive interstitial lung disease (ILD), particularly in Asian patients, and is associated with a distinct set of clinical features, including skin and systemic manifestations. The clinical features of Anti-DM5-associated idiopathic inflammatory myopathy include skin manifestations such as photosensitive rash, and systemic features like arthralgia, Raynaud's phenomenon, and dysphagia due to pharyngeal muscle involvement 1.

Key Clinical Features

  • Aggressive ILD, which can be rapidly progressive and life-threatening
  • Skin manifestations, including photosensitive rash
  • Systemic features, such as arthralgia, Raynaud's phenomenon, and dysphagia
  • Cardiac involvement, including arrhythmias or myocarditis
  • Constitutional symptoms, like fever, fatigue, and weight loss

Management

Early recognition of these clinical features is crucial for prompt initiation of immunosuppressive therapy, typically starting with high-dose corticosteroids and often requiring additional agents like methotrexate, azathioprine, or mycophenolate mofetil for long-term management 1. Some key points to consider in management include:

  • High-dose corticosteroids should be administered systemically, either orally or intravenously, in moderate to severe cases
  • Methotrexate (MTX) should be started at a dose of 15-20 mg/m2/week, preferably administered subcutaneously, at disease onset
  • Intravenous immunoglobulin may be a useful adjunct for resistant disease, particularly when skin features are prominent
  • Mycophenolate mofetil (MMF) may be a useful therapy for muscle and skin disease, including calcinosis It is essential to note that the presence of anti-DM5 antibodies is associated with a higher risk of malignancy, particularly in older patients, necessitating thorough cancer screening 1.

From the Research

Clinical Features of Anti-DM5-associated Idiopathic Inflammatory Myopathy

The clinical features of Anti-DM5 (Dermyositis-specific autoantibody 5)-associated idiopathic inflammatory myopathy include:

  • Skin manifestations such as Gottron's sign, heliotrope rash, mechanic's hand, and skin ulcers 2, 3, 4
  • Systemic manifestations including interstitial lung disease (ILD), arthritis, and cardiac involvement 5, 4, 6
  • Muscle weakness and inflammatory myopathy on biopsy 3, 4
  • Normal or elevated creatine kinase levels 3, 4

Skin Manifestations

The skin manifestations of Anti-DM5-associated idiopathic inflammatory myopathy are:

  • Gottron's sign: a characteristic skin lesion found on the hands and feet 2, 3, 4
  • Heliotrope rash: a purple rash found on the face and arms 2, 3, 4
  • Mechanic's hand: a skin lesion found on the hands, characterized by thickening and cracking of the skin 2
  • Skin ulcers: found in some patients with Anti-DM5-associated idiopathic inflammatory myopathy 2

Systemic Manifestations

The systemic manifestations of Anti-DM5-associated idiopathic inflammatory myopathy include:

  • Interstitial lung disease (ILD): found in some patients with Anti-DM5-associated idiopathic inflammatory myopathy 5, 4
  • Arthritis: found in some patients with Anti-DM5-associated idiopathic inflammatory myopathy 4, 6
  • Cardiac involvement: including second-degree heart block, found in some patients with Anti-DM5-associated idiopathic inflammatory myopathy 6

Treatment and Outcome

The treatment and outcome of Anti-DM5-associated idiopathic inflammatory myopathy include:

  • Glucocorticoids and immunosuppressants: used to treat the disease 5, 4, 6
  • Favorable treatment outcome: found in some patients with Anti-DM5-associated idiopathic inflammatory myopathy, with improvement in symptoms and remission of the disease 4, 6

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.